TMBIM6 antagonist-1 is a potent TMBIM6 antagonist that inhibits the interaction between TMBIM6 and mTORC2, thereby reducing mTORC2 activity and modulating TMBIM6-mediated Ca²⁺ release; it significantly and dose-dependently inhibits cell viability in HT1080, MCF7, MDA-MB-231, and SKBR3 cancer cell lines with IC₅₀ values of 1.7±0.1 μM, 2.6±0.4 μM, 2.6±0.5 μM, and 2.4±0.4 μM, respectively; it suppresses cell migration in HT1080, MCF7, MDA-MB-231, and SKBR3 cells (but not in TMBIM6 knockout HT1080 cells); it downregulates AKT phosphorylation at Ser473 in wild-type HT1080 cells; and in vivo, it significantly impairs tumor growth driven by HT1080 and MDA-MB-231 cells in a xenograft mouse model when administered intraperitoneally at 1 mg/kg, five days per week for 25 days.